New Orleans, LA, USA, June 11, 2016 - Dr. Bijan Najafi, Professor of Surgery and Director of Clinical Research at the Baylor College of Medicine presented the first released results of the second pilot study at University of Arizona’s Southern Arizona Limb Salvage Alliance (SALSA) at the American Diabetes Association (ADA) Scientific Sessions in New Orleans.
This study, under the direction of Dr. David Armstrong, tested Orpyx’s SurroSense Rx™ with 19 participants with diabetic peripheral neuropathy and at high risk of diabetic foot ulcers over a three-month period.
Dr. Najafi reported that by the third month, patients receiving a higher number of alerts offloaded their feet more successfully, compared with those who received a lower number of alerts (55% vs. 17%, P < 0.01). In addition, patients whose wear time increased during the study tended to have more alerts per hour, compared with other participants (0.82 vs. 0.36 alerts; P = 0.09), suggesting that increasing the number of alerts a user receives may be a viable path to maintaining adherence among patients with diabetes who are introduced to novel mobile health devices.
“The SurroSense Rx® continues to show tremendous promise in improving the lives of diabetic patients everywhere. We’re excited with the first results of this clinical study and look forward to seeing the comprehensive results of this study published soon.” said Dr. Breanne Everett, CEO and Co-Founder of Orpyx Medical Technologies Inc.
“In 2015 alone, the total costs of diabetes in the US were $320 billion, a 31% increase since 2012. Patients with diabetes carry a 25% lifetime risk of foot ulceration, which are prone to infections that may lead to tissue death or debilitating amputation.” said Dr. Bijan Najafi. ”This is an important area for scientific and industry focus.”
About Southern Arizona Limb Salvage Alliance (SALSA)
The Southern Arizona Limb Salvage Alliance (SALSA) is a collaborative clinical and research alliance dedicated to advancing care of the diabetic foot and preventing amputations in North America and worldwide.
About Orpyx Medical Technologies Inc.
Orpyx Medical Technologies Inc. (“Orpyx”) is a wearable pressure sensor technology company focused on medical applications. Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot ulcers which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. Additionally, this problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.
For more information, please contact:
Marketing Manager, Orpyx Medical Technologies Inc.
+1 403 460 0216 ext. 501